Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAAOI-1 (Sodium Benzoate) for Schizophrenia
NCT00960219Phase 2Completed
- Sponsor
- China Medical University Hospital
- Start
- Apr 2009
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sodium benzoate in schizophrenia (2 arms), sponsored by China Medical University Hospital. Primary endpoints: Positive and Negative Syndrome Scale at 6 weeks, Scale for the Assessment of Negative Symptoms at 6 weeks and 3 more. Started Apr 2009; status: completed.
02
Drugs
sodium benzoate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00960219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00960219.